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Abstract
p38 mitogen-activated protein kinase (MAPK) acts downstream in the signaling pathway that includes receptor activator of
NF-kB (RANK), a powerful inducer of osteoclast formation and activation. We investigated the role of p38 MAPK in
parathyroid hormone related protein (PTHrP)-induced osteoclastogenesis in vitro and PTHrP-induced bone resorption in
vivo. The ability of FR167653 to inhibit osteoclast formation was evaluated by counting the number of tartrate-resistant acid
phosphatase positive multinucleated cells (TRAP-positive MNCs) in in vitro osteoclastgenesis assays. Its mechanisms were
evaluated by detecting the expression level of c-Fos and nuclear factor of activated T cells c1 (NFATc1) in bone marrow
macrophages(BMMs) stimulated with sRANKL and M-CSF, and by detecting the expression level of osteoprotegerin (OPG)
and RANKL in bone marrow stromal cells stimulated with PTHrP in the presence of FR167653. The function of FR167653 on
bone resorption was assessed by measuring the bone resorption area radiographically and by counting osteoclast number
per unit bone tissue area in calvaria in a mouse model of bone resorption by injecting PTHrP subcutaneously onto calvaria.
Whole blood ionized calcium levels were also recorded. FR167653 inhibited PTHrP-induced osteoclast formation and PTHrP-
induced c-Fos and NFATc1 expression in bone marrow macrophages, but not the expression levels of RANKL and OPG in
primary bone marrow stromal cells treated by PTHrP. Furthermore, bone resorption area and osteoclast number in vivo
were significantly decreased by the treatment of FR167653. Systemic hypercalcemia was also partially inhibited. Inhibition of
p38 MAPK by FR167653 blocks PTHrP-induced osteoclastogenesis in vitro and PTHrP-induced bone resorption in vivo,
suggesting that the p38 MAPK signaling pathway plays a fundamental role in PTHrP-induced osteoclastic bone resorption.
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Introduction
Parathyroid hormone related protein (PTHrP), a potent
stimulator of osteoclastic bone resorption, was first identified as
a causative factor for humoral hypercalcemia of malignancy [1]. A
number of clinicopathological and experimental studies have
shown that cancer cell-derived PTHrP promotes osteoclastic bone
resorption and contributes to the development and progression of
cancer metastasis to bone [2–5]. PTHrP stimulates osteoclasto-
genesis by acting on osteoblasts and/or bone marrow stromal cells
to increase receptor activator of NF-kB ligand (RANKL)
expression and reduce osteoprotegerin (OPG) expression, not by
acting directly on osteoclast precursors [6]. Osteoclast precursors
that express RANK, a tumor necrosis factor (TNF) receptor family
member, recognize RANKL and differentiate into osteoclasts in
the presence of macrophage/monocyte colony stimulating factor
(M-CSF). OPG is a soluble decoy receptor for RANKL and has
the ability to inhibit osteoclastogenesis. Therefore, a relative
increase of RANKL versus OPG expression by PTHrP activates
osteoclastic bone resorption [7–12].
Additionally, a body of evidence suggested that p38 mitogen-
activated protein kinase (MAPK) is downstream of the RANK
signaling pathway and plays an important role in osteoclast
differentiation. The expression of dominant-negative forms of p38
MAPK in RAW264.7 cells inhibited RANKL-induced differenti-
ation of these cells into osteoclasts [13]. Li et al used
pyridinylimidazole SB203580, a specific inhibitor of p38 MAPK,
to study p38 MAPK function and demonstrated that p38 MAPK
is required for osteoclast differentiation [14].
FR167653 was first discovered as a potent inhibitor of TNFa
and interleukin (IL)-1b production in lipopolysaccharide-stimulat-
ed human monocytes and phytohemagglutinin-M-stimulated
human lymphocytes [15,16]. FR167653 inhibits the activation of
p38 MAPK by suppressing the phosphorylation of p38 MAPK,
preferentially affecting its a isoform, but not the c isoform [17–19].
FR167653 is effective in treating inflammation, relieving trauma
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reported that M-CSF-dependent sRANKL- and TNFa-induced
osteoclast formation in primary bone marrow cells, and collagen-
induced arthritis in rats were inhibited by FR167653 [23].
However, the relationship of p38 MAPK and PTHrP in
osteoclastogenesis and bone resorption is still unclear.
Here we investigate the role of FR167653 on PTHrP-induced
osteoclastogenesis, local bone resorption, and hypercalcemia. We
found that FR167653 not only blocked osteoclast differentiation
induced both by PTHrP and sRANKL with down regulation of c-
Fos and NFATc1 in bone marrow macrophages without affecting
RANKL and OPG expression in bone marrow stromal cells, but
also alleviated bone resorption induced by PTHrP with partial
reduction of hypercalcemia in vivo.
Materials and Methods
Animal and reagents
All animal experiments in this study strictly followed a protocol
approved by the Institutional Animal Care and Use Committee of
Osaka University (approval number: 338). Six-week-old male ddy
mice and four- to eight-week-old male BDF1 mice were purchased
from Japan SLC (Hamamatsu, Japan) and Oriental Yeast (Tokyo,
Japan), respectively. Human recombinant PTHrP (1–34) was
purchased from Peptide Institute (Osaka, Japan). M-CSF and
soluble recombinant RANKL were purchased from PeproTeck
EC (London, UK). FR167653 was provided by Asteras Pharma
(Osaka, Japan). c-Fos and actin antibodies were purchased from
Cell Signaling Technology (Danvers, USA). NFATc1 antibody
was bought from BD Biosciences Pharmingen (Franklin Lakes,
USA).
Primary bone marrow cell culture
Bone marrow cells were collected by removing the tibias and
femurs from ddy mice and flushing the bone cavity with serum-
free alpha-minimum essential medium (aMEM; Invitrogen,
Carlsbad, CA). A sample of 7.5610
5 cells in a volume of
0.5 ml/well were cultured in aMEM supplemented with 10% fetal
bovine serum (FBS; Equitech-Bio, Kerrville, TX) in the presence
of PTHrP (45 ng/ml). Some cultures received an additional
treatment of 10 mM, 1 mM or 0.1 mM FR167653. The medium
was changed every two days, replacing half of the medium with
0.25 ml fresh medium containing 90 ng/ml PTHrP and 20 mM,
2 mM and 0.2 mM FR167653. After six days of culture, adherent
cells were stained for tartrate-resistant acid phosphatase (TRAP),
an osteoclast marker enzyme, using a TRAP staining kit (Hokudo,
Sapporo, Japan). TRAP-positive multinucleated cells (MNCs) with
three or more nuclei were counted as osteoclasts.
M-CSF-dependent bone marrow macrophage (MDBMMs)
culture
M-CSF-dependent bone marrow macrophages (MDBMMs)
were cultured as described previously [23–25]. Briefly, bone
marrow cells (5610
6) were cultured in the aMEM supplemented
with 10% FBS, and M-CSF at the concentration of 100 ng/ml in
100 mm dishes for three days. Then the cells were washed and
harvested with 0.02% ethylene diamine tetra-acetate (EDTA) in
phosphate-buffered saline, and seeded at a density of 3610
5 into
100-mm culture dishes in the presence of M-CSF (100 ng/ml).
After three more days of culture, the adherent cells were
considered as MDBMMs.
For osteoclast culture, MDBMMs were digested with 0.25%
Trypsin-EDTA (Invitrogen) and 1610
4/well cells were re-plated
into 48-well plates in the presence of sRANKL (100 ng/ml) and
M-CSF (100 ng/ml). Some cultures were treated with FR167653.
After five more days of culture, adherent cells were fixed and
stained for TRAP. TRAP-positive MNCs containing three or
more nuclei were counted as osteoclasts.
For the detection of the c-Fos and NFATc1expression,
MDBMMs were treated by each concentration of FR167653 for
1 hour. Then, sRANKL and M-CSF were added. After another
24 or 48 hour culture, the cells were collected for RNA extraction
and protein extraction.
Real-time polymerase chain reaction
Total RNA was extracted from bone marrow cells (for genes of
OPG and RANKL) or bone marrow macrophages (for genes of c-
fos and NFATc1) by using the RNeasy Mini Kit (Qiagen,
Valencia, CA). RNase-free DNase Set (Qiagen) was used to
remove the residual DNA. Five micrograms of RNA were reverse
transcribed into cDNA with Ready-To-Go You-Prime First-
Strand Beads (Amersham Bioscience, Piscataway, NJ). In order to
reduce pipetting error, the final volume of cDNA was reached by
adding four volumes RNase-free distilled water to the original
cDNA. The resultant product was subjected to real-time PCR.
Real-time PCR was performed in a Light Cycler (Roche
Applied Science, Indianapolis, IN) with Light cycler-DNA Master
SYBR Green I (Roche Applied Science) and were performed
according to the standard protocol recommended by the
manufacturer. Reverse transcription was followed by 40 cycles of
PCR (denaturation at 95uC for 10 min addition of 1-second at
94uC, 5-second annealing at 58, 60, 61, 59 and 58uC for OPG,
RANKL, c-fos, NFATc1 and GAPDH, respecticvely, and 10-
second extension at 72uC, and each of optimal fluorescence
measurement temperature for 1 second as the amplification and
quantification programs, 60–99uC with a heating rate of 0.1uC per
second as the melting curve program, and finally, cooling to 40uC.
The primer sequences are as follows:
RANKL: sense: 59-CAC CAT CAG CTG AAG ATA GT-39
antisense: 59-CCA AGA TCT CTA ACA TGA CG-39
OPG: sense: 59-TGGGACCAAAGTGAATGCC-
GAGA-39
antisense: 59-AGCTGCTCTGTGGTGAGGTTC-39
c-fos: sense: 59-CTGGTGCAGCCCACTCTGGT-39
antisense: 59- CTTTCAGCAGATTGGCAATC-39
N F A T c 1 :s e n s e :5 9- CAACGCCCTGACCACCGATA-39
antisense: 59- GGCTGCCTTCCGTCTCATAG-39
GAPDH: sense: 59-ACCACAGTCCATGCCATCAC-39
antisense: 59- TCCACCACCCTGTTGCTGTA-39
Semiquantitative RANKL, OPG, c-fos and NFATc1 expression
levels were determined by normalizing with GAPDH expression level.
Western blotting
Cells were washed twice with ice-cold PBS and lysed with a
buffer containing 20 mM Tris–HCl, 150 mM NaCl, 1% riton X-
100, and inhibitors for proteases and phosphatases [25]. Cell
lysates were centrifuged at 10,000 g for 20 min and the
supernatants were collected. Twenty micrograms of cellular
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nitrocellulose membranes. Membranes were blocked with 5%
skim milk in Tris-buffered saline containing 0.1% Tween 20 for
1 h and incubated overnight at 4uC with primary antibodies.
Membranes were washed, incubated with appropriate secondary
antibodies conjugated to horseradish peroxidase for 1 h, and
developed using a chemiluminescence system. Relative protein
expression was calculated from band densities obtained in three
experiments using UMax PowerLook 1100 scanner (Taiwan) and
TotalLab gel image analysis software (Nonlinear Dynamics, New
England, UK).
PTHrP-induced bone resorption in an animal model
Male BDF1 mice aged four weeks were injected daily for five
days (from day one to five) with PTHrP (18 mg/day; Figure 1).
PTHrP was injected into the subcutaneous tissue over the left side
of the calvaria twice daily in a volume of 10 ml as described
previously [26,27]. This delivery method produces an exaggerated
resorptive response in the calvarial bone, as well as a systemic
effect as indicated by hypercalcemia. Animals were housed in an
accredited facility and all procedures used in the animal
experiments complied with the standards described in the Osaka
University Medical School Guidelines for the Care and Use of
Laboratory Animal.
Treatment Protocol
All animals were additionally treated with FR167653 or distilled
water, injected subcutaneously on the mice back as in the protocol
shown in Figure 1. Treatment was initiated two days before
PTHrP injection.
Before treatment, 50 ml of whole blood was collected retro-
orbitally into heparinized capillary tubes (Radiometer, Copenha-
gen, Denmark) and basal whole-blood ionized calcium levels were
determined with a calcium level analyzer (model ABL505,
Radiometer; n=3 from treatment group and control group,
respectively). The treatment group (n=7) was treated with 30 mg/
kg of FR167653 twice daily while the control group (n=5) was
treated with distilled water for seven days (including pretreatment).
At day three and five, blood samples were taken three hours after
injection of PTHrP retro-orbitally to determine the levels of
hypercalcemia. Mice were killed on day six, which was 12 hours
after the last injection of PTHrP.
Quantitative analysis of bone resorption
Calvaria were retrieved from sacrificed mice and immersed into
neutral buffered formalin. Radiographs were taken with the MX-
20 Specimen Radiography System (Faxitron X-ray, Wheeling, IL).
The images were scanned into a computer with a flatbed scanner
and saved in RGB color format. The quantitative analysis of
calvarial bone resorption was processed with an image analysis
software package, WinROOF (Mitani, Fukui, Japan). The
thresholds were determined by clicking five typical bone resorptive
areas.
After decalcification, the anterior and posterior portions of the
calvaria were removed just anterior to coronal suture and posterior
to lambdoid suture, respectively. The left part of the calvaria was
cut into three strips, embedded in paraffin and sectioned. Sections
were stained to detect TRAP activity and counterstained with
hematoxylin.
Histomorphormetic analysis was performed on the left side of
the calvaria to determine the number of osteoclasts present in the
bone. The area measured consisted of six visual fields extending
from sagittal suture toward the lateral muscle attachment and
included all of the bone and marrow spaces. PTHrP-treated
calvaria showed a distinct dorsal periosteal pattern of resorption
and endosteal resorption. Thus, the osteoclast number represented
the sum of periosteal and endosteal measurements. Results were
recorded as osteoclast number per unit bone tissue area measured
(OcN-BTA). All measurements were made by tracing the section
image onto a digitizing platen with the aid of a cameral lucida
attachment and WinROOF image analysis software.
Statistical analysis
All analyses were reported as mean 6S.D. Statistical signifi-
cance was evaluated by Student’s t-test or one factor analysis of
variance (ANOVA) followed by a Tukey-Kramer post test using a
statistical software package, JMP (SAS institute, Cary, NC).
Results
FR167653 inhibits Osteoclast formation in two different
cell culture systems
To determine whether FR167653 blocks osteoclastogenesis in
vitro, we investigated osteoclastogenesis in a primary bone marrow
cells stimulated by PTHrP. As expected, TRAP-positive MNCs
(osteoclasts) was formed in primary bone marrow cultures treated
with PTHrP. As shown in Figure 2, osteoclast formation induced
by PTHrP at day six was inhibited by addition of FR167653 in a
dose-dependent manner. At the concentration of 10 mM,
FR167653 nearly eliminated osteoclast formation.
Unlike bone marrow cells, MDBMM cells are a homogeneous
bone marrow macrophage population with a contamination by
stromal cells of less than 1 in 1,000 cells. As shown in Figure 3,
MDBMM cells formed TRAP-positive osteoclasts when treated
with RANKL together with M-CSF even in the absence of stromal
cells. FR167653 added to the cultures significantly inhibited
RANKL-induced osteoclast formation in a dose-dependent
manner. These data suggest that FR167653 acts directly on
osteoclast precursors to inhibit osteoclast formation.
OPG and RANKL expression levels in bone marrow cells
were not affected by FR167653 treatment
To further elucidate the mechanism of FR167653 inhibition of
PTHrP-induced osteoclastogenesis, we examined the effects of
FR167653 on the OPG and RANKL expression in bone marrow
stromal cells.
Figure 1. Animal model and treatment protocol. The PTHrP-
induced bone resorption animal model was established by injecting
PTHrP (18 mg/day) onto the dorsal surface of the mice calvaria daily for
five days (day 1 to 5). Animals in the treatment (n=7) or the control
group (n=5) were injected with FR167653 (30 mg/kg twice daily) or
distilled water, respectively, daily for seven days, initiating from two
days before PTHrP injection. 50 ml of whole blood was collected retro-
orbitally before treatment, on day three, and on day five to determine
whole-blood ionized calcium levels. Mice were sacrificed on day six,
12 hours after the last injection of PTHrP.
doi:10.1371/journal.pone.0023199.g001
FR167653 Inhibits PTHrP Induced Bone Resorption
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23199Bone marrow stromal cells were obtained by culturing primary
bone marrow cells for ten days. Almost all non-adherent or
loosely attached hematopoietic cells in the primary bone marrow
cell cultures were removed by pipetting each time when the
medium was changed. Expression of RANKL and OPG mRNA
in bone marrow stromal cells was increased or decreased,
respectively, within three days of PTHrP treatment. The
increased expression even lasted 6 days post-treatment. Even at
ad o s eo f1 0mM, FR167653 has no detectable effect on the
PTHrP-mediated expression of RANKL and OPG mRNA
(Figure 4). Taken together, these results further suggest that
FR167653 acts directly on osteoclast precursors (rather than on
stromal cells or osteoblasts) in its role as an inhibitor of osteoclast
formation.
Expression of c-Fos and NFATc1 in osteoclast precursors
(MDBMMs) were inhibited by FR167653
In order to investigate the mechanism of FR167653 on
osteoclast formation in osteocalst precursor cells, we detected the
expression of c-Fos and NFATc1 in bone marrow macrophage
cells by western blotting and RT-PCR following the FR167653
treatments. As shown in Figure 5, the mRNA expression levels of
c-fos and NFATc1 were dramatically increased when treated with
sRANKL and these effects were inhibited by FR167653 in a dose-
dependent manner(p,0.05; Figure 5A). Similarly, c-Fos and
NFATc1 protein levels were decreased in the presence of
FR167653 dose-dependently (Figure 5B).
FR167653 reduces PTHrP-induced bone resorption in
vivo
We next examined the effects of FR167653 on PTHrP-induced
bone resorption in vivo. Animal models of bone resorption were
established by direct injection of PTHrP onto the dorsal surface of
mice calvaria. Radiographic evidence of bone resorption com-
prises zones of increased radiolucency in the calvaria. Histolog-
ically, these changes are associated with significant periosteal bone
resorption on the dorsal calvarial surface and increased marrow
spaces, accompanied with increased numbers of osteoclasts.
FR167653 significantly reduced the radiographic bone resorption
areas (p,0.05; Figure 6) and osteoclast number (as determined on
histological sections) (p,0.005, Figure 7).
Figure 2. FR167653 inhibits TRAP-positive osteoclast forma-
tion in PTHrP-treated bone marrow cells. A. Bone marrow cells
were treated with PTHrP (45 ng/ml) and FR167653 for six days. TRAP-
positive MNCs with three or more nuclei were counted as osteoclasts.
n=9. *: p,0.001 versus the group treated only with PTHrP. B. TRAP
staining for bone marrow cells stimulated with PTHrP (45 ng/ml). a: no
treatment. b: FR167653 (0.1 mM). c: FR167653 (1 mM). d: FR167653
(10 mM). TRAP-positive MNCs appear as red cells with clear peripheries.
doi:10.1371/journal.pone.0023199.g002
Figure 3. Effects of FR167653 on osteoclast formation in M-
CSF-dependent bone marrow macrophages treated with
sRANKL. A. Osteoclast formation assay using M-CSF-dependent bone
marrow macrophages (MDBMMs) prepared as described in the
Materials and Methods section. TRAP-positive MNCs with three or
more nuclei were counted as osteoclasts. n=6. *: p,0.001 versus the
group treated only with sRANKL. B. TRAP staining for MDBMMs
stimulated by sRANKL (100 ng/ml). a: No treatment. b: FR167653
(0.1 mM). c: FR167653 (1 mM). d: FR167653 (10 mM).
doi:10.1371/journal.pone.0023199.g003
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PTHrP-induced systemic hypercalcemia
PTHrP is one of the causative factors of the hypercalcemia that
is associated with malignancy, since PTHrP can induce systemic
bone resorption. Furthermore, extensive local bone resorption is to
some extent a contributory cause of hypercalcemia. For this
reason, we monitored whole-blood ionized calcium levels in our
experimental system. The level of whole-blood ionized calcium
was increased at three hours after PTHrP injection on days 3 and
5 compared to day 1. When additionally treated with FR167653,
the whole-blood ionized calcium concentration was significantly
decreased at day 3, but not day 5. This suggest the functional
involvement of p38 MAPK in PTHrP-induced systemic hyper-
calcemia (Figure 8).
Discussion
There are several reports about p38 MAPK inhibitor,
SB203580, inhibits osteoclast differentiation in RAW264 induced
by RANKL [28] or in bone marrow cells induced by 1a, 25-
(OH)2 D3 and prostaglandin E2 (PGE2) [14]. Previously, we
reported that M-CSF-dependent sRANKL- and TNFa-induced
osteoclast formation in primary bone marrow cells, and collagen-
induced arthritis in rats were inhibited by FR167653 [23]. Here
we further show that FR167653, a selective inhibitor of p38
MAPK, strongly inhibits osteoclast differentiation in PTHrP-
treated bone marrow cell cultures.
We also investigated the mechanism of FR167653 involved in
the inhibition of osteoclast formation. Most osteoclastgenesis
inducers are thought to stimulate osteoclast formation via up-
Figure 4. FR167653 does not affect OPG or RANKL expression by PTHrP-treated stromal cells. Bone marrow stromal cells were seeded
into six-well plates and treated with PTHrP (90 ng/ml) and FR167653 at various concentrations for three and six days. Real-time PCR was used to
determine the OPG or RANKL gene expression levels. The results are shown as mean 6S.D. of three independent experiments. Expression of RANKL
and OPG mRNA was increased or decreased, respectively, within three days of PTHrP treatment, and lasted 6 days post-treatment. The expression
level of RANKL and OPG did not changed by adding 1 mMo r1 0mM FR167653 (P.0.05).
doi:10.1371/journal.pone.0023199.g004
Figure 5. The effects of FR167653 on sRANKL-induced c-Fos and NFATc1 expression level in M-CSF-dependent bone marrow
macrophages (MDBMMs). Bone marrow macrophages were treated with 100 ng/ml M-CSF and 100 ng/ml sRANKL without or with FR67653 at the
indicated concentration. After 24 h incubation, cells were harvested and subjected to RT-PCR (A). For western blot analysis (B), the cells were
incubated for 48 h. Expression of c-Fos and NFATc1 in both mRNA and protein levels were increased following the sRANKL treatment. This
enhancement was inhibited by FR167653 in a dose dependent manner. The results are shown as mean 6S.D. of three independent experiments. *:
p,0.05 versus the group treated only with sRANKL.
doi:10.1371/journal.pone.0023199.g005
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expression as mediated by osteoblast or bone marrow stromal
cells [25,29]. In our study, however, even the highest concentra-
tion of FR167653 that was tested (10 mM) has no effect on
RANKL and OPG expression by PTHrP-stimulated primary
bone marrow stromal cells. These data suggest that p38 MAPK is
not involved in the regulation of PTHrP-mediated bone
resorption-related functions of osteoblasts, including regulation
of RANKL and OPG expression. This is consistent with previous
results that SB203580 has no effect on RANKL and OPG
expression by primary osteoblast stimulated with 1a, 25- (OH)2D3
and PGE2 [14]. Together, the data suggest that p38 MAPK is
involved in the differentiation of osteoclast precursors, rather than
in the function of supporting cell such as osteoblasts or bone
marrow stromal cells.
However, the current study found that the up-regulation of c-
Fos and NFATc1expression treated with RANKL in osteoclast
precursor cells (MDBMMs) were inhibited by FR167653 in a
dose-dependent manner in both mRNA and protein levels. This
strongly suggested the inhibition of osteoclast differentiation by
FR167653 is involved in regulating c-Fos and NFATc1 expression
in osteoclast precursor cells. The similar results were reported by
using SB203580 [30]. These findings, together with the present
study, suggest that p38 MAPK-mediated signal propagation down
to c-Fos and NFATc1 are of fundamental importance for the
differentiation of osteoclast precursors into osteoclasts.
In our animal experiments, local injection of PTHrP on calvaria
caused significant bone resorption and systemic hypercalcemia,
and increased osteoclast number. Treatment with FR167653
successfully reduced bone resorption and osteoclast number in
calvaria, and eventually protected the calvaria from serious
osteoclastic dystruction induced by locally administered PTHrP.
However, some relieving effect on hypercalcemia was observed. In
our hands, inhibition of p38 MAPK by FR167653 significantly
decreased the whole-blood calcium level on day 3. However, there
is no difference in blood calcium level between the FR167653
treatment group and the control group at day 5.
It was reported that recombinant human OPG is effective in
inhibiting bone resorption and hypercalcemia induced by PTHrP
in vivo [27]. Treatment with chimeric form of OPG in combination
with PTHrP (20 mg/day) maintained whole blood ionized calcium
Figure 6. The effect of FR167653 on PTHrP-induced bone
resorption. The calvarial bone resorption was measured radiograph-
ically on the left side (area marked by yellow line) where treated by
direct subcutaneous injection of PTHrP. A. Treatment by FR167653
reduced the bone resorption area (*: P,0.005). DW:distilled water. B.
Representative X-rays of mouse calvaria with PTHrP-induced bone
resorption. a: control group (treated with DW). b: FR167653 treatment
group.
doi:10.1371/journal.pone.0023199.g006
Figure 7. The effects of FR167653 on osteoclast number in
calvaria from PTHrP-treated animals. A. Osteoclast number per
unit bone area (OcN-BTA) was measured histologically as described in
the Materials and Methods section. Treatment of FR167653 reduces the
number of osteoclasts (*: P,0.005). B. TRAP staining and counterstain
with hematoxylin on calvaria sections. a: Histological section of animals
treated with DW. b: Histological section of animals treated with
FR167653. Osteoclasts are indicated by arrowheads.
doi:10.1371/journal.pone.0023199.g007
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FR167653 was given subcutaneously, it should have act
systemically. The concentration of calcium in extracellular fluids
is under control by a complex homeostatic system strictly that
includes the parathyroid glands, kidneys, bones, and intestines
[31,32]. An increase of extracellular calcium concentration is
sensed by a calcium-sensing receptor (CaR) in the plasma
membrane of parathyroid gland cells and the kidney which in
turn affects parathyroid hormone, calcitonin, and 1, 25 (OH) 2D3
secretion. Although intracellular signaling systems regulated by the
CaR are still in obscurity, recent evidence suggests that MAPK
pathways are activated by CaR [33,34]. For example, calcium
homeostasis by angiotensin II in adrenal glomerulosa cells is
mediated by activation of p38 MAPK pathways [35]. These
observations may help us to understand the surprisingly small
effect of p38 MAPK pathway blockade on regulating hypercalce-
mia induced by PTHrP because the inhibition of p38 MAPK
pathway may block CaR signaling pathway as well, which in turn
causes reduced reaction to extracellular Ca
2+ in tissues that express
CaR. The detailed mechanism for why inhibition of p38 MAPK
partially prevents hypercalcemia even though it is effective in
reducing bone resorption merits further studies.
FR167653 has been used in several inflammatory disease
models and no obvious adverse events were observed [15–19]. In
our previous in vivo study [23], we found no significant side effects
with daily treatments of 32 mg/kg, a dose found to be safe and
effective in other inflammation models as well [36]. In the present
study, we also found that there is no significant side effects when
twice daily treatment with 30 mg/kg FR167653 for about 1 week.
Long-term injection of FR167653 may lead to toxic events;
indeed, one study demonstrated that FR167653 treatment
increased plasma creatine and lactate dehydrogenase levels in
rats [37]. Clearly, the potentially adverse effects of FR167653,
including its modulation of calcium homeostasis, need to be
studied extensively.
In conclusion, our data indicate that a potent p38 MAPK
inhibitor, FR167653, blocks PTHrP-induced osteoclastogenesis in
vitro, and bone resorption and hypercalcemia in vivo. Our results
indicate that the responses of other tissues or organs to the p38
MAPK inhibitor may affect calcium homeostasis. This study
provides a plausible explanation and target for PTHrP-induced
osteoclastogenesis, which will help us to understand the mecha-
nism of bone resorption-related diseases.
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